Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$309.38 - $337.38 $51.2 Million - $55.8 Million
-165,500 Reduced 13.56%
1,054,800 $340 Million
Q2 2024

Aug 14, 2024

SELL
$262.75 - $319.31 $140 Million - $171 Million
-534,700 Reduced 30.47%
1,220,300 $381 Million
Q1 2024

May 15, 2024

BUY
$268.87 - $324.56 $177 Million - $213 Million
657,500 Added 59.91%
1,755,000 $499 Million
Q4 2023

Feb 14, 2024

SELL
$255.7 - $288.46 $4.99 Million - $5.62 Million
-19,500 Reduced 1.75%
1,097,500 $316 Million
Q3 2023

Nov 14, 2023

BUY
$218.65 - $271.46 $45.3 Million - $56.2 Million
207,000 Added 22.75%
1,117,000 $300 Million
Q2 2023

Aug 14, 2023

BUY
$214.27 - $253.37 $12.9 Million - $15.3 Million
60,200 Added 7.08%
910,000 $202 Million
Q1 2023

May 15, 2023

SELL
$225.79 - $275.2 $41.9 Million - $51 Million
-185,400 Reduced 17.91%
849,800 $205 Million
Q4 2022

Feb 14, 2023

SELL
$229.03 - $291.01 $26.3 Million - $33.4 Million
-114,900 Reduced 9.99%
1,035,200 $272 Million
Q3 2022

Nov 14, 2022

SELL
$224.46 - $253.15 $86.8 Million - $97.9 Million
-386,800 Reduced 25.17%
1,150,100 $259 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.